Skip to main content

Table 2 Co-morbidities in patients with AF attending GUH, 2017 (N = 159)

From: Poor outcomes associated with antithrombotic undertreatment in patients with atrial fibrillation attending Gondar University Hospital: a retrospective cohort study

 

All patients N = 159

Potential Undertreatment N = 103

According to guideline treatment N = 56

P-value

CHF

101 (63.5)

63 (61.2%)

38 (67.9%)

0.402

Hypertension

54 (34)

41 (39.8%)

13 (23.2%)

0.080

History of stroke/TIA

30 (18.9)

10 (9.7%)

20 (35.7%)

0.000

Vascular disease

36 (22.6)

21 (20.4%)

15 (26.8%)

0.357

DM

8 (5.0)

6 (5.8%)

2 (3.6%)

0.714

Anemia (Hemoglobin< 12/13)

33 (20.8)

22 (21.4%)

11 (19.64%)

0.799

IHD/ACS

14 (8.8)

10 (9.7%)

4 (7.1%)

0.772

Hyperthyroidism

22 (13.8)

16 (15.5%)

6 (10.7%)

0.400

Cardiomyopathy

5 (3.1)

3 (2.9%)

2 (3.6%)

1.000

Cardiomegaly

43 (27.0)

23 (22.3%)

20 (35.7%)

0.070

Increased LV wall thickness

5 (3.1)

1 (1.0%)

4 (7.1%)

0.052

LVH

18 (11.3)

12 (11.7%)

6 (10.7%)

0.859

LA enlargement

10 (6.3)

6 (5.8%)

4 (7.1%)

0.742

Liver disease (LFT > 3XULN)

11 (6.9%)

6 (5.8%)

5 (8.9%)

0.461

History of bleeding

5 (3.1%)

2 (1.9%)

3 (5.4%)

0.236